STOCK TITAN

Heart Test Laboratories, Inc. - $HSCS STOCK NEWS

Welcome to our dedicated page for Heart Test Laboratories news (Ticker: $HSCS), a resource for investors and traders seeking the latest updates and insights on Heart Test Laboratories stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Heart Test Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Heart Test Laboratories's position in the market.

Rhea-AI Summary
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) reminds shareholders to vote ahead of its 2023 Annual Meeting of Stockholders on January 17, 2024. All shareholders on record as of November 20, 2023, are entitled to participate and vote. Shareholders are encouraged to read the company’s definitive proxy statement on Schedule 14A, filed with the SEC on December 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
none
-
Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) reported financial results for Q2 fiscal 2024, highlighting transformative changes through agreements with the Icahn School of Medicine at Mount Sinai, FDA confirmation for a standard 510(k) submission pathway, and expanded international distribution channels. The company also raised $9.6 million in net proceeds from sales of common stock and converted $1.1 million of debt to equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
-
Rhea-AI Summary
HeartSciences (Nasdaq: HSCS; HSCSW) has received FDA confirmation to change the clearance pathway for its MyoVista® wavECG™ device and associated AI-ECG algorithm to a more standard 510(k) submission from the De Novo process. The company aims to deliver innovative AI-ECG diagnosis from millions of existing ECG devices worldwide and is on track for FDA submission in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
Rhea-AI Summary
Heart Test Laboratories, Inc. (Nasdaq: HSCS; HSCSW) announced the closing of license agreements with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) to develop and commercialize electrocardiographic AI algorithms and assets. The licenses result in Icahn Mount Sinai becoming a shareholder in the company. HeartSciences aims to bring new AI-powered ECG capabilities to market, enabling the early detection of heart disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.45%
Tags
AI
-
Rhea-AI Summary
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd to be used in its heart screening program for the Association of Garda Sergeants and Inspectors. Cardiact has placed an initial order for 2,400 patient tests and established a new referral pathway directly to cardiology. This announcement follows recent positive developments, including agreements with Icahn School of Medicine at Mount Sinai and the creation of a new FDA product classification for AI-ECG algorithms, positioning AI-ECG as a transformative tool for early heart disease detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
-
Rhea-AI Summary
HeartSciences announces transformative agreements with Icahn Mount Sinai and files FDA Pre-Submission Request
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
Rhea-AI Summary
HeartSciences, an AI-powered medical technology company, has been issued new patents in Brazil and the UAE, bringing its total patent portfolio to 33 international patents and 9 US patents. CEO Andrew Simpson expects AI to drive significant growth in the ECG market to $25 billion per year by 2032. HeartSciences also recently signed agreements with Mount Sinai to expand its cardiovascular disease screening capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
none
-
Rhea-AI Summary
HeartSciences CEO to present at Maxim Group's Virtual Tech Conference Series: Emerging Growth in A.I.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.59%
Tags
conferences acquisition
-
Rhea-AI Summary
HeartSciences partners with Icahn Mount Sinai to commercialize AI algorithms for cardiovascular disease detection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none
Rhea-AI Summary
HeartSciences reports Q1 fiscal 2024 business update and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
Heart Test Laboratories, Inc.

Nasdaq:HSCS

HSCS Rankings

HSCS Stock Data

7.42M
56.25M
16.01%
1.84%
0.21%
Surgical Appliance and Supplies Manufacturing
Manufacturing
Link
United States of America
SOUTHLAKE